Clinical trials: CtDNA
Breast Cancer
Immune Tumor Stroma Factors and Pathologic Complete Response After Neoadjuvant Chemotherapy in Early Breast Cancer
This prospective cohort study aims to identify immune-related predictive factors of response to neoadjuvant chemotherapy in patients with early breast cancer.
- Trial name
- AKRA (NCT07407244)
- Testing
- Neoadjuvant Chemotherapy
- Where
- Slovenia
- Volunteers
- 268 people
- Sponsor
- Institute of Oncology Ljubljana
Colon Cancer, Colon Adenomas
Plasma ctDNA in Patients Undergoing Diagnostic Colonoscopy
When the DNA inside of human cells undergoes certain alterations (mutations), the cells may develop into a cancer. The cancer cells may shed this DNA into the blood stream.
- Conditions
- Colon Cancer, Colon Adenomas, Colon Polyps
- Trial name
- NCT02665299
- Where
- United States
- Volunteers
- 206 people, healthy volunteers welcome
- Sponsor
- Pathway Genomics
Colon Cancer
CtDNA in Adjuvant Chemotherapy of Stage III Colon Cancer (REVISE Trial)
Colon cancer is one of the most common malignant tumors with an increasing incidence rate in China. Surgical resection is still the main treatment for colon cancer at present.
- Trial name
- REVISE (NCT06242418)
- Testing
- FOLFOXIRI, XELOX
- Where
- 9 sites in China
- Volunteers
- 60 people
- Sponsor
- West China Hospital
Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage I
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
In this study circulating tumor DNA (ctDNA) blood testing is used to detect the residual blood cancer. If residual cancer using this blood test is detected there may be at higher risk of having the cancer return.
- Conditions
- Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage I, Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage III
- Trial name
- NCT04585477
- Testing
- AVENIO ctDNA Surveillance Kit, Durvalumab, Durvalumab (Imfinzi) alone or in combination with platinum-based chemotherapy
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Stanford University
HPV Positive Pelvic Cancer
Circulating Tumor DNA for the Early Detection of HPV-positive Pelvic Cancer Relapses (CIRCA-HPV)
ctDNA detection in patients with previously treated, HPV-induced, stage II or III invasive pelvic cancer and who are currently in post-treatment follow-up.
- Trial name
- CIRCA-HPV (NCT03739775)
- Testing
- Blood sampling
- Where
- 5 sites in France
- Volunteers
- 172 people
- Sponsor
- Institut Curie
Non-Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer
NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) Trial
This is a multicenter screening protocol designed to identify patients with NSCLC who have tumor mutations in the KEAP1 or NRF2/NFE2L2 genes in order to determine potential eligibility for a biomarker selected clinical trial…
- Conditions
- Non-Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer, Non-Squamous Non-Small Cell Neoplasm of Lung, KEAP1 Gene Mutation
- Trial name
- NCT04698681
- Where
- 63 sites in United States
- Volunteers
- 20 people
- Sponsor
- Calithera Biosciences, Inc
Prognostic Cancer Model
Prognostic Significance of ctDNA in HL
Specific somatic mutations using ctDNA will be analyzed in predefined subgroups of cHL (e.g., age <60 and ≥ 60 years, EBV). These mutations will be correlated with response to the treatment in the first line, in the relapse…
- Trial name
- NCT06263530
- Where
- 5 sites in Czechia
- Volunteers
- 500 people
- Sponsor
- Interni hematologicka klinika FNKV
Hodgkin Lymphoma
Circulating Tumor DNA Genotyping for Biological Monitoring of Patients Treated in the FIL-Rouge Clinical Trial
Prospective, multicenter, non-interventional, biological study ancillary to FIL-Rouge clinical trial (NCT03159897) enrolling patients affected by Advanced-stage Hodgkin Lymphoma, ABVD-based upfront treatment in 19 centers in…
- Trial name
- FIL-RougeBIO (NCT05066555)
- Where
- 13 sites in Italy
- Volunteers
- 100 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma
Molecular Characterization of CTCs and ctDNA in Blood and Plasma Samples From Patients With Metastatic and/or Hormone-Resistant Prostate Cancer
This research trial studies molecular characterization of circulating tumor cells (CTCs) and circulating tumor (ct) deoxyribonucleic acid (DNA) in blood and plasma samples from patients with prostate cancer that has spread to…
- Trial name
- NCT02370355
- Testing
- Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Southern California
Thyroid Cancer
Investigating Utility of ctDNA and Tumour Evolution in Advanced Thyroid Cancer
Although most thyroid cancers are treated and cured successfully there are still 30% who recur after many years. This will eventually progress and at this point may become incurable with treatment options including complex and…
- Trial name
- NOMINATE (NCT05837260)
- Testing
- Sample collection only
- Where
- United Kingdom
- Volunteers
- 120 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma
A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma
The purpose of this study is to find out how many people with B-cell lymphoma who are at high risk for central nervous system/CNS relapse test positive for cerebral spinal fluid/CSF ctDNA but test negative for CNS involvement…
- Conditions
- Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Stage III High Grade B-Cell Lymphoma, Stage IV High Grade B-Cell Lymphoma
- Trial name
- NCT06736613
- Testing
- Cerebral Spinal Fluid ctDNA
- Where
- 7 sites in United States
- Volunteers
- 50 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer, Metastatic Cervical Cancer
HER-Seq: A Blood-based Screening Study to Identify Patients With HER2 Mutations for Enrollment Into Clinical Research Studies of Neratinib
This is a multi-center, observational genomic screening protocol to identify participants whose tumors harbor somatic mutations in the ERBB2 (HER2) gene, as measured in circulating tumor DNA (ctDNA) .
- Trial name
- NCT03786107
- Testing
- Almac HER-Seq Assay
- Where
- 22 sites in United States, France and 5 more
- Volunteers
- 1,583 people
- Sponsor
- Puma Biotechnology, Inc.
HPV Positive Oropharyngeal Squamous Cell Carcinoma
ctDNA Liquid Biopsy for Early Assessment of Residual Disease in HPV-associated Head and Neck Cancer (Clear-HPVca)
The purpose of this study is to test a new liquid biopsy assay for detecting residual disease after surgery in patients with HPV-associated head and neck cancer.
- Trial name
- Clear-HPVca (NCT06730412)
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- Massachusetts Eye and Ear Infirmary
Bladder Cancer, Bladder Cancer, Metastatic
Treatment Of Metastatic Bladder Cancer at the Time Of Biochemical reLApse Following Radical Cystectomy
Immunotherapy (checkpoint inhibitors) is approved as first and second line treatment to patients with metastatic bladder cancer.
- Trial name
- TOMBOLA (NCT04138628)
- Testing
- Atezolizumab
- Where
- 5 sites in Denmark
- Volunteers
- 154 people
- Sponsor
- Jørgen Bjerggaard Jensen
Non-small Cell Lung Cancer, Esophageal Cancer
Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers
Patients with resectable solid primary cancers and even limited number of metastases are potentially curable. However, most patients develop recurrences despite surgery.
- Conditions
- Non-small Cell Lung Cancer, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer
- Trial name
- NCT02838836
- Testing
- Study sample collection
- Where
- United States
- Volunteers
- 620 people, healthy volunteers welcome
- Sponsor
- University of Missouri-Columbia
Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone
Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer
This study investigates how well radium-223 works in treating patients with castration-resistant prostate cancer than has spread to the bones (bone metastases).
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
- Trial name
- NCT04489719
- Testing
- Biospecimen Collection, Questionnaire Administration, Radium Ra 223 Dichloride
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- University of Washington
Colorectal Cancer, Surgery
MRD Application in Colorectal Cancer Patients
We first collect tumor tissue and adjacent tissue to peform the WES sequencing, then collect blood after postoperative surgery 1, 3. 6, 9, 12, 18, 24 month to detect ctDNA.
- Conditions
- Colorectal Cancer, Surgery, Chemotherapy Effect
- Trial name
- NCT06028516
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shandong First Medical University
Colorectal Cancer, Rectal Cancer
A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and Chemotherapy
The researchers are doing this study to find out whether the combination of botensilimab and balstilimab (BOT/BAL), followed by balstilimab alone, is an effective treatment for people with microsatellite stable (MSS) colorectal…
- Trial name
- NCT07227636
- Testing
- Botensilimab, Balstilimab
- Where
- 7 sites in United States
- Volunteers
- 284 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Colorectal Tumor
Comparison of Diagnostic Sensitivity Between ctDNA Methylation and CEA in Colorectal Cancer
This is a prospective diagnostic study. This study is to compare the performance between circulating tumor DNA (ctDNA) methylation and carcinoembryonic antigen (CEA) in detecting colorectal tumor.
- Trial name
- NCT05558436
- Testing
- Genome-wide methylation profiling
- Where
- China
- Volunteers
- 662 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Langerhans Cell Histiocytosis
Response-adapted Luvometinib With or Without Cytarabine in Langerhans Cell Histiocytosis
This single-center, prospective, interventional phase 2 study evaluates a response-adapted treatment strategy for patients aged 10 years and older with histologically confirmed Langerhans cell histiocytosis requiring systemic…
- Trial name
- LUCAS (NCT07728201)
- Testing
- Luvometinib, Luvometinib, Cytarabine.
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University